Brokerages predict that Recro Pharma, Inc. (NASDAQ:REPH) will report earnings per share (EPS) of ($0.53) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Recro Pharma’s earnings. The lowest EPS estimate is ($0.59) and the highest is ($0.45). Recro Pharma posted earnings of ($0.83) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 36.1%. The company is expected to issue its next quarterly earnings results on Thursday, August 10th.

On average, analysts expect that Recro Pharma will report full-year earnings of ($2.35) per share for the current year, with EPS estimates ranging from ($2.51) to ($2.24). For the next year, analysts anticipate that the business will report earnings of ($2.60) per share, with EPS estimates ranging from ($3.25) to ($2.08). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that follow Recro Pharma.

Recro Pharma (NASDAQ:REPH) last released its earnings results on Thursday, May 11th. The specialty pharmaceutical company reported ($0.42) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.15. The firm had revenue of $18.74 million during the quarter, compared to analyst estimates of $15.58 million. Recro Pharma had a negative net margin of 45.15% and a negative return on equity of 61.09%.

A number of analysts have recently issued reports on the stock. Roth Capital set a $20.00 target price on shares of Recro Pharma and gave the stock a “buy” rating in a research note on Saturday, May 13th. Zacks Investment Research cut shares of Recro Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. Janney Montgomery Scott cut shares of Recro Pharma from a “buy” rating to a “fair value” rating and dropped their target price for the company from $21.00 to $6.50 in a research report on Wednesday, June 14th. Finally, Aegis restated a “buy” rating and issued a $11.00 target price on shares of Recro Pharma in a research report on Monday, March 27th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Recro Pharma presently has a consensus rating of “Buy” and an average price target of $14.14.

In other Recro Pharma news, major shareholder Stonepine Capital Management, sold 217,308 shares of the company’s stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $7.70, for a total transaction of $1,673,271.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider James E. Flynn sold 110,447 shares of the company’s stock in a transaction on Wednesday, June 14th. The stock was sold at an average price of $6.39, for a total transaction of $705,756.33. The disclosure for this sale can be found here. Insiders have sold a total of 1,187,699 shares of company stock worth $8,749,514 in the last quarter. 21.60% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in REPH. Numeric Investors LLC acquired a new position in Recro Pharma during the fourth quarter valued at $556,000. Opus Point Partners Management LLC acquired a new position in Recro Pharma during the fourth quarter valued at $322,000. Acadian Asset Management LLC acquired a new position in Recro Pharma during the first quarter valued at $150,000. Janney Montgomery Scott LLC increased its position in Recro Pharma by 17.8% in the first quarter. Janney Montgomery Scott LLC now owns 12,485 shares of the specialty pharmaceutical company’s stock valued at $109,000 after buying an additional 1,885 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in Recro Pharma by 3.0% in the first quarter. Wells Fargo & Company MN now owns 17,200 shares of the specialty pharmaceutical company’s stock valued at $150,000 after buying an additional 500 shares during the last quarter. Hedge funds and other institutional investors own 64.19% of the company’s stock.

Recro Pharma (NASDAQ:REPH) traded up 0.56% on Thursday, reaching $7.24. 12,967 shares of the company’s stock were exchanged. Recro Pharma has a 12 month low of $5.81 and a 12 month high of $12.50. The firm’s 50-day moving average is $7.40 and its 200-day moving average is $7.67. The firm’s market cap is $137.92 million.

TRADEMARK VIOLATION WARNING: “Recro Pharma, Inc. (NASDAQ:REPH) Expected to Post Earnings of -$0.53 Per Share” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/07/18/recro-pharma-inc-nasdaqreph-expected-to-post-earnings-of-0-53-per-share.html.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related stocks with our FREE daily email newsletter.